Thrombocytopenia resulting from sensitivity to GPIIb-IIIa inhibitors

Seminars in Thrombosis and Hemostasis

Volumn 30, Issue 5, 2004, Pages 569-577

  Aster, Richard H ^a,b   Curtis, Brian R ^a   Bougie, Daniel W ^a  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Abciximab; Eptifibatide; GPIIb IIIa inhibitors; Thrombocytopenia; Tirofiban

Indexed keywords

EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; IMMUNOGLOBULIN G; TIROFIBAN;

ANTIBODY RESPONSE; ANTICOAGULANT THERAPY; DIFFERENTIAL DIAGNOSIS; HEMOSTASIS; HUMAN; IMMUNOPATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; LIGANDS; MODELS, CHEMICAL; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RISK FACTORS; THROMBOCYTOPENIA; TYROSINE;

EID: 7044269109     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-835677     Document Type: Review

References (71)

1. Coller BS. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest 1997;99:1467-1471
2. Verstraete M. Synthetic inhibitors of platelet glycoprotein IIb/IIIa in clinical development. Circulation 2000;101:E76-E80
3. Bennett JS, Mousa S. Platelet function inhibitors in the year 2000. Thromb Haemost 2001;85:395-400
4. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999;353:227-231
5. Kereiakes DJ. Oral platelet glycoprotein IIb/IIIa inhibitors. Coron Artery Dis 1999;10:581-594
6. Tam SH, Sassoli PM, Jordan RE, Nakada MT. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation 1998;98:1085-1089
7. Nurden P, Poujol C, Durrieu-Jais C, et al. Labeling of the internal pool of GP IIb-IIIa in platelets by c7E3 Fab fragments (abciximab): flow and endocytic mechanisms contribute to the transport. Blood 1999;93:1622-1633
8. Christopoulos C, Mackie I, Lahiri A, Machin S. Flow cytometric observations on the in vivo use of Fab fragments of a chimeric monoclonal antibody to platelet glycoprotein IIb/ IIIa. Blood Coagul Fibrinolysis 1993;4:729-737
9. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmaco-dynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GPIIb/IIIa receptor blockade. Circulation 1998;97:1680-1686
10. EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696
11. CAPTURE investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429-1435
12. Berkowitz SD, Sane DC, Sigmon KN, et al. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. J Am Coll Cardiol 1998;32:311-319
13. Jubelirer SJ, Koenig BA, Bates MC. Acute profound thrombocytopenia following C7E3 Fab (abciximab) therapy: case reports, review of the literature and implications for therapy. Am J Hematol 1999;61:205-208
14. Tcheng JE, Kereiakes DJ, Lincoff AM, et al. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 2001;104:870-875
15. Kereiakes DJ, Berkowitz SD, Lincoff AM, et al. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. Am Heart J 2000;140:74-78
16. Dillon WC, Eckert GJ, Dillon JC, Ritchie ME. Incidence of thrombocytopenia following coronary stent placement using abciximab plus dopidogrel or ticlopidine. Catheter Cardiovasc Interv 2000;50:426-430
17. Guzzo JA, Nichols TC. Possible anaphylactic reaction to abciximab. Catheter Cardiovasc Interv 1999;48:71-73
18. Iakovou Y, Manginas A, Melissari E, Cokkinos DV. Acute profound thrombocytopenia associated with anaphylactic reaction after abciximab therapy during percutaneous coronary angioplasty. Cardiology 2001;95:215-216
19. Curtis BR, Swyers J, Divgi A, McFarland JG, Aster RH. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 2002;99:2054-2059
20. Vahdat B, Canavy I, Fourcade L, et al. Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment. Catheter Cardiovasc Interv 2000;49:177-180
21. Moshiri S, Di Mario C, Liistro F, Melissano G, Chiesa R, Colombo A. Severe intracranial hemorrhage after emergency carotid stenting and abciximab administration for postoperative thrombosis. Catheter Cardiovasc Interv 2001;53:225-228
22. Jenkins LA, Lau S, Crawford M, Keung YK. Delayed profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1998;97:1214-1215
23. Reddy MS, Carmody TJ, Kereiakes DJ. Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy. Catheter Cardiovasc Interv 2001;52:486-488
24. Kaluski E, Leitman M, Khiger I, Cotter G. Delayed thrombocytopenia following abciximab therapy. J Cardiovasc Interv 2001;4:151-155
25. Sharma S, Bhambi B, Nyitray W, et al. Delayed profound thrombocytopenia presenting seven days after use of abciximab (ReoPro). J Cardiovasc Pharmacol Ther 2002;7:21-24
26. Desai M, Lucore CL. Uneventful use of tirofiban as an adjunct to coronary stenting in a patient with a history of abciximab-associated thrombocytopenia 10 months earlier. J Invasive Cardiol 2000;12:109-112
27. Coto H. Platelet receptor glycoprotein IIb/IIIa inhibition with eptifibatide in a patient with thrombocytopenia after treatment with abciximab. J Invasive Cardiol 2000;12:528-531
28. Aster RH. Drug-induced immune thrombocytopenia: an overview of pathogenesis. Semin Hematol 1999;36:2-6
29. Peter K, Schwarz M, Ylanne J, et al. Related articles, links free full text induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood 1998;92:3240-3249
30. Peter K, Straub A, Kohler B, et al. Platelet activation as a potential mechanism of GPIIb/IIIa inhibitor-induced thrombocytopenia. Am J Cardiol 1999;84:519-524
31. Ndoko S, Poujol C, Combrie R, Nurden A, Nurden P. Paradoxical platelet activation was not observed on dissociation of abciximab from GPIIb-IIIa complexes. Thromb Haemost 2002;87:317-322
32. Gawaz M, Neumann FJ, Schomig A. Evaluation of platelet membrane glycoproteins in coronary artery disease: consequences for diagnosis and therapy. Circulation 1999;99:E1-E11
33. Rossi F, Rossi E, Pareti FI, Colli S, Tremoli E, Gallo L. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion. Haematologica 2001;86:192-198
34. Cazes E, Nurden P, Nurden AT. Abciximab binding to glycoprotein IIb-IIa and protein tyrosine phosphorylation in human platelets. Blood 1999;93:4019-4020
35. Osterland CK, Harboe M, Kunkel HG. Anti-gamma globulin factors in human sera revealed by enzymatic splitting of anti-Rh antibodies. Vox Sang 1963;8:133-152
36. Persselin JE, Stevens RH. Anti-Fab antibodies in humans: predominance of minor immunoglobulin G subclasses in rheumatoid arthritis. J Clin Invest 1985;76:723-730
37. Knight DM, Wagner C, Jordan R, et al. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol 1995;32:1271-1281
38. Curtis BR, Divgi A, Garritty M, Aster RH. Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug. J Thromb Haemost 2004;2:985-992
39. Warkentin TE. Laboratory testing for heparin-induced thrombocytopenia. J Thromb Thrombolysis 2000;10(supp1 1): 35-45
40. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with dopidogrel. N Engl J Med 2000;342:1773-1777
41. Elmi F, Peacock T, Schiavone J. Isolated profound thrombocytopenia associated with clopidogrel. J Invasive Cardiol 2000;12:532-535
42. Christopolous CG, Machin SJ. A new type of pseudothrombocytopenia: EDTA-mediated agglutination of platelets bearing Fab fragments of a chimeric antibody. Br J Haematol 1994;87:650-652
43. Sane DC, Damaraju LV, Topol EJ, et al. Occurrence and clinical significance of pseudo-thrombocytopenia during abciximab therapy. J Am Coll Cardiol 2000;36:75-83
44. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol 1997;80:11B-20B
45. Kondo K, Umemura K. Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab. Clin Pharmacokinet 2002;41:187-195
46. Sieffert D, Stern AM, Ebling W, et al. Prospective testing for drug-dependent antibodies reduces the incidence of thrombocytopenia observed with the small molecule glycoprotein IIb/IIIa antagonist roxifiban: implications for the etiology of thrombocytopenia. Blood 2003;101:58-63
47. PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998;339:436-443
48. PRISM-PLUS Trial Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-1497
49. McClure MW, Berkowitz SD, Sparapani R, et al. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. Circulation 1999;99:2892-2900
50. RESTORE Trial Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-1453
51. Paradiso-Hardy FL, Madan M, Radhakrishnan S, Hurden S, Cohen EA. Severe thrombocytopenia possibly related to readministration of eptifibatide. Catheter Cardiovasc Interv 2001;54:63-67
52. Bougie DW, Wilker PR, Wuitschick ED, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002;100:2071-2076
53. Salengro E, Mulvihill NT, Farah B. Acute profound thrombocytopenia after use of eptifibatide for coronary stenting. Catheter Cardiovasc Interv 2003;58:73-75
54. Tanaka KA, Vega JD, Kelly AB, Hanson SR, Levy JH. Eptifibatide-induced thrombocytopenia and coronary bypass operation. J Thromb Haemost 2003;1:392-394
55. Nagge J, Jackevicius C, Dzavik V, Ross JR, Seidelin P. Acute profound thrombocytopenia associated with eptifibatide therapy. Pharmacotherapy 2003;23:374-379
56. Morel O, Jesel L, Chauvin M, Freyssinet JM, Toti F. Eptifibatide-induced thrombocytopenia and circulating procoagulant platelet-derived microparticles in a patient with acute coronary syndrome. J Thromb Haemost 2003;1:2685-2687
57. Rezkalla SH, Hayes JJ, Curtis BR, Aster RH. Eptifibatide-induced acute profound thrombocytopenia presenting as refractory hypotension. Catheter Cardiovas Interv 2003;58:76-79
58. Yoder M, Edwards RF. Reversible thrombocytopenia associated with eptifibatide. Ann Pharmacother 2002;36:628-30c
59. Suleiman M, Gruberg L, Hammerman H, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention. J Invasive Cardiol 2003;15:319-323
60. Khaykin Y, Paradiso-Hardy FL, Madan M. Acute thrombocytopenia associated with eptifibatide therapy. Can J Cardiol 2003;19:797-801
61. Brassard JA, Curtis BR, Cooper RA, et al. Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology. Thromb Haemost 2002;88:892-897
62. Billheimer JT, Dicker IB, Wynn R, et al. Evidence that thrombocytopenia observed in humans treated with orally bioavailable glycoprotein IIb/IIIa antagonists is immune mediated. Blood 2002;99:3540-3546
63. Matzdorff AC, Kuhnel G, Kemkes-Matthes B, Pralle H, Voss R, Fareed J. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro. J Lab Clin Med 2000;135:247-255
64. Cox D, Smith R, Quinn M, Theroux P, Crean P, Fitzgerald DJ. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 2000;36:1514-1519
65. Holmes MB, Sobel BE, Cannon CP, Schneider DJ. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in patients with unstable coronary syndromes. Thrombolysis in myocardial infarction. Am J Cardiol 2000;85:491-493
66. Frelinger AL, Furman MI, Krueger LA, Barnard MR, Michelson AD. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation. Circulation 2001;104:1374-1379
67. Seiffert D, Thomas BE, Bradley JD, et al. Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist. Platelets 2003;14:179-187
68. Bednar B, Cook JJ, Holahan MA, et al. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood 1999;94:587-599
69. Dunkley S, Lindeman R, Evans S, Casten R, Jepson N. Evidence of platelet activation due to tirofiban-dependent platelet antibodies: double trouble. J Thromb Haemost 2003;1:2248-2250
70. Kouns WC, Kirchhofer D, Hadváry P, et al. Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor. Blood 1992;80:2539-2547
71. 3. J Biol Chem 1996;271:20315-20321